News

News | March 13, 2025

Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) Systems

Press Release | January 10, 2025

Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine

News | January 10, 2025

Lilly ventures into pulmonary fibrosis with startup Mediar

Press Release | January 10, 2025

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies

News | December 19, 2024

Vittoria Biotherapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of VIPER-101

Press Release | December 11, 2024

Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies

News | December 9, 2024

Vittoria Biotherapeutics Presents Positive Preclinical Data at 66th Annual ASH Meeting Supporting its Novel Approach to Engineered CAR-T Cell Therapies

Press Release | November 13, 2024

TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development

News | November 12, 2024

Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

News | November 11, 2024

Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers

News | November 7, 2024

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations November 07, 2024 08:30 ET | Source: Palvella Therapeutics

News | October 24, 2024

Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

News | October 23, 2024

Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies

News | October 14, 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

News | October 10, 2024

Cyrus Biotechnology Congratulates David Baker, 2024 Nobel Laureate in Chemistry and Cyrus Co-Founder

Press Release | September 17, 2024

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

News | September 12, 2024

Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

Press Release | September 3, 2024

Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

Press Release | August 14, 2024

Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results

Press Release | July 24, 2024

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

News | July 22, 2024

Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology

Press Release | July 10, 2024

Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Press Release | July 9, 2024

Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies

Press Release | June 27, 2024

« Back Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Press Release | June 20, 2024

āshibio Raises $40M in Seed and Series A Financing to Advance Therapies for Bone and Connective Tissue Disorders

Press Release | May 28, 2024

Affini-T Therapeutics Announces First Patient Dosed in KRAS G12V Phase 1 Program and Presentation of Trial-in-Progress Poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Video | May 6, 2024

BIOSECURE Act Discussion featuring Cartier Esham, Ph.D. of BIO

Press Release | April 2, 2024

Freenome Announces Topline Results for PREEMPT CRC® to Validate the First Version of its Blood-Based Test for the Early Detection of Colorectal Cancer

News | March 25, 2024

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

News | February 21, 2024

Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases

Press Release | February 15, 2024

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

Press Release | February 8, 2024

Metagenomi Announces Pricing of Initial Public Offering

Press Release | February 4, 2024

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Press Release | December 14, 2023

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

Press Release | December 7, 2023

Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma

Press Release | December 5, 2023

Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

Press Release | November 28, 2023

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

Press Release | November 20, 2023

Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases

News | October 25, 2023

A new era in medicine: unraveling the evolution and future of gene therapy

News | October 23, 2023

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington’s Disease

News | October 19, 2023

Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer

News | October 16, 2023

ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023

Press Release | October 5, 2023

Kyowa Kirin to Acquire Orchard Therapeutics

Press Release | September 26, 2023

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Press Release | September 21, 2023

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

News | September 20, 2023

ImCheck has been short-listed among the top 10 “Biotech et Medtech” companies for the 2023 edition of Les Trophées des Futures Licornes, which rewards the growth potential of innovative French companies.

Press Release | September 5, 2023

Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb

Press Release | September 5, 2023

Star Therapeutics raises $90 million financing to accelerate its pipeline of novel antibody therapies and growth of its portfolio companies

News | August 25, 2023

Investing long-term in the cell & gene therapies of the future (Podcast with Geeta Vemuri and David McCall)

Press Release | August 23, 2023

Pyxis Oncology Successfully Completes Acquisition of Apexigen

News | August 17, 2023

Patent Awarded for Primary Template-Directed Amplification, Further Strengthening BioSkryb Genomics’ Core Technologies

Press Release | August 15, 2023

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

Press Release | August 3, 2023

Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA

Press Release | August 1, 2023

Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology

Press Release | August 1, 2023

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Press Release | July 20, 2023

Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations and Topline Results from Phase 2b CODY Study in Gorlin Syndrome

Press Release | June 28, 2023

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors

News | June 21, 2023

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

Press Release | June 20, 2023

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

Press Release | June 15, 2023

Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

News | June 15, 2023

ImCheck selected as laureate of the new French Tech 2030 program

Press Release | June 15, 2023

Walgreens and Freenome Establish Partnership to Increase Diversity in Research for the Early Detection of Cancer

Press Release | June 5, 2023

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

Press Release | June 2, 2023

Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer

Press Release | June 1, 2023

Dr. Robin Edwards and Dr. David Ferry join Dragonfly’s Clinical Leadership Team to help Manage its Growing Clinical Pipeline

Press Release | May 30, 2023

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

Press Release | May 24, 2023

Pyxis Oncology to Acquire Apexigen

Press Release | May 22, 2023

Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd

Press Release | May 22, 2023

Freenome Acquires Global Immunodiagnostics Developer Oncimmune Ltd

Press Release | May 19, 2023

Metagenomi to Present New Data for Its Novel Gene-Editing Systems at the 26th American Society of Gene + Cell Therapy (ASGCT) Annual Meeting

Press Release | May 19, 2023

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

Press Release | May 19, 2023

Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT

News | May 16, 2023

Cyrus Bio Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article

Press Release | April 27, 2023

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform

Press Release | April 26, 2023

Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines

Press Release | April 18, 2023

ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023

News | April 16, 2023

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Press Release | April 13, 2023

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline

News | March 26, 2023

Investing long-term in the cell & gene therapies of the future

News | March 22, 2023

Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

Press Release | March 16, 2023

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

News | March 15, 2023

Passage of FDA Modernization Act 2.0 Opens Opportunities for New Alternative Methods in Drug Development

Press Release | March 13, 2023

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

Press Release | March 9, 2023

Palvella Therapeutics Announces Positive Topline Results from Phase 2 Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations, a Serious, Rare Genetic Skin Disease with No FDA-approved Therapies

News | March 7, 2023

Carisma Therapeutics Closes Merger with Sesen Bio

Press Release | March 6, 2023

Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million

Press Release | March 3, 2023

Affini-T Therapeutics to Present Data from Lead Oncogenic Driver Candidate at AACR Special Conference: Targeting RAS

Press Release | March 2, 2023

Metagenomi Recognized as One of World’s Most Innovative Companies by Fast Company

Press Release | March 1, 2023

DICE Therapeutics Announces Late-Breaking Presentation at the 2023 American Academy of Dermatology (AAD) Annual Meeting

News | February 27, 2023

Pathway to Cures Appoints Investment Committee

Press Release | February 2, 2023

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

Press Release | February 1, 2023

Dr. Joseph E. Eid, Who Led Merck’s Pioneering Clinical Development of KEYTRUDA®, joins Dragonfly Therapeutics as President of R&D

Press Release | January 31, 2023

Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

Press Release | January 27, 2023

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Press Release | January 22, 2023

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

Press Release | January 18, 2023

Freenome Partners with Geisinger for the Sanderson Study

Education | January 12, 2023

Agent Capital’s Associate, Jonathan Ark’s PhD Work Published in Cell

Press Release | January 11, 2023

Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)

Press Release | January 9, 2023

Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones

Press Release | January 6, 2023

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Press Release | January 6, 2023

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

Press Release | January 5, 2023

Palvella Therapeutics Announces Series D Financing of Up to $37.7 Million to Accelerate Late-Stage Development and Support Commercialization of Novel Therapies for Serious, Rare Genetic Skin Diseases

Press Release | January 5, 2023

Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH

Press Release | January 5, 2023

Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline

News | January 4, 2023

Top Life Sciences Startups to Watch in 2023

Press Release | January 4, 2023

Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009

News | January 3, 2023

Viewpoint: Expanding TRIPS waiver is bad for innovation

News | December 15, 2022

Metagenomi Announces Publication of Data in Nature Communications Describing Novel, Ultra-Small Nucleases for Gene Editing

Press Release | December 15, 2022

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Press Release | December 12, 2022

Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA

Press Release | December 12, 2022

Freenome Presents Research Highlighting The Promise of Identifying Drug-Response Biomarker for DLBCL Patients

Press Release | December 8, 2022

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Press Release | December 8, 2022

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Press Release | November 24, 2022

Proud to congratulate ImCheck’s scientific founder, Prof. Daniel Olive, on his election as President of the French Society of Immunology

Press Release | November 15, 2022

ElevateBio and Affini-T Therapeutics Announce Partnership to Advance Affini-T’s T Cell Therapy Programs Targeting Core Oncogenic Drivers

News | November 14, 2022

Ionis, Metagenomi pen Big Pharma-sized genetic target pact that could total almost $3B

Press Release | November 11, 2022

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Press Release | November 7, 2022

Affini-T Therapeutics to Present Preclinical Data from its Lead Programs Targeting KRAS G12V at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Press Release | November 7, 2022

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Press Release | November 1, 2022

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Press Release | October 11, 2022

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for Psoriasis

Press Release | October 3, 2022

Metagenomi Announces Opening of Manufacturing Facility for its Next Generation CRISPR Gene-Editing Systems and Therapies

News | September 22, 2022

Affini-T Therapeutics Named to the 2022 Endpoints 11

News | September 22, 2022

Metagenomi Named an Endpoints 11 Winner

News | September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

Press Release | September 10, 2022

ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

Press Release | September 1, 2022

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Press Release | July 26, 2022

Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

Press Release | July 11, 2022

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Press Release | July 5, 2022

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Press Release | June 21, 2022

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Press Release | June 13, 2022

ImCheck Closes Upsized EUR 96 Million (USD 103 Million) Financing to Advance Clinical Program of First-in-human Gamma-delta T Cell Activating Antibody and Accelerate Development of Disruptive Immunotherapeutic Pipeline

Press Release | May 15, 2022

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

Press Release | May 2, 2022

Gilead follows Big Pharma peers to Dragonfly’s pond in $300M deal for natural killer cell engagers

Press Release | April 20, 2022

Dragonfly Therapeutics Announces Multi-Target Expansion of its Research Collaboration with AbbVie to Develop Novel Therapeutic Candidates for Immune-Mediated Diseases

Press Release | April 8, 2022

ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022

Press Release | April 8, 2022

Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting

News | March 22, 2022

Affini-T Therapeutics Completes $175 Million Financing Co-Led by Vida Ventures and Leaps by Bayer to Advance Groundbreaking T Cell Therapies for Solid Tumor Patients with Oncogenic Driver Mutations

Press Release | March 1, 2022

Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb

Press Release | February 28, 2022

Freenome Launches the Vallania Study for the Early Detection of Multiple Cancers

News | February 28, 2022

Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia

Press Release | February 24, 2022

Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Press Release | February 3, 2022

Orchard Therapeutics Announces Historic Agreement Making Libmeldy Available by NHS England for MLD Patients

News | January 28, 2022

Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar

News | January 25, 2022

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

Press Release | January 19, 2022

Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment

Press Release | January 6, 2022

Zenas BioPharma Appoints Dr. John Orloff to Board of Directors

News | December 16, 2021

Verge Genomics Secures $98 Million in New Financing

Press Release | December 9, 2021

Interius BioTherapeutics Announces Granting of US Patent to Support in Vivo Cell-Specific Gene Delivery Platform

News | December 1, 2021

Entrada Therapeutics: Advancing A New Class Of Medicines Called EEV

News | December 1, 2021

Cyrus Biotechnology

News | December 1, 2021

Zenas BioPharma

Press Release | November 23, 2021

Dragonfly Announces Merck Opt-In on Second TriNKET

News | November 12, 2021

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021

News | October 20, 2021

imCheck Publishes Comprehensive Overview of the Developmenet Resumts of its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Cells in Science Translational Medicine

Press Release | October 18, 2021

Dragonfly Therapeutics Announces Sixth Dragonfly Drug to be Licensed by Bristol Myers Squibb and Receipt of Milestone Payments Following First Patient Dosing of Two TriNKET™ Immunotherapies

Press Release | October 13, 2021

Agent Capital Adds Dr. John Orloff as Venture Partner

Press Release | October 11, 2021

Pyxis IPO leads way as four life science firms kick off 4Q, raising nearly $500M

Press Release | October 8, 2021

Pyxis Oncology Raises $168M in Upsized IPO

Press Release | October 8, 2021

Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells

Press Release | October 4, 2021

New Study Finds Freenome’s Multiomics Approach Successful in Detecting Pancreatic Cancer

Press Release | October 4, 2021

Research Highlights Freenome’s Blood Test for Colorectal Cancer to Primary Care Physicians

Press Release | October 1, 2021

ImCheck to Present Updated Patient Response Data from the EVICTION Trial and Additional ICT01 Results at the SITC Annual Meeting 2021

News | September 28, 2021

Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine

News | September 17, 2021

Skyhawk Therapeutics Completes New Investment Round

News | September 17, 2021

DICE Therapeutics Announces Pricing of Upsized Initial Public Offering

News | September 17, 2021

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

News | September 14, 2021

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

Press Release | September 14, 2021

Skyhawk Therapeutics Completes New Investment Round

Press Release | September 8, 2021

Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

Press Release | August 18, 2021

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases

News | July 13, 2021

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells

News | June 1, 2021

Alloy Therapeutics and Pyxis Oncology Form Kyma Therapeutics to Develop Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases

News | May 18, 2021

Interius BioTherapeutics Raises $76M Series A Financing to Advance Breakthrough Cell and Gene Therapy Platform

Press Release | March 31, 2021

Entrada Therapeutics Announces Closing of $116 Million Series B Financing

Press Release | March 30, 2021

Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics

Press Release | March 18, 2021

Pyxis Oncology Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Multiple Antibody-Drug Conjugates

News | March 18, 2021

CAR-M era begins as Carisma doses first patient

News | January 8, 2021

DiCE gets its ‘library’ card ready as it speeds development of DNA database-derived molecules with more investor cash

News | January 7, 2021

CARISMA Therapeutics Completes Series B Funding to Advance Development of Novel CAR-Macrophage Immunotherapies

Press Release | December 21, 2020

Orchard Therapeutics Receives EC Approval for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD)

News | November 20, 2020

Lilly, Precision Biosciences team up on Duchenne gene therapy in $135M deal

Press Release | November 5, 2020

Orchard Therapeutics Announces New OTL-201 Clinical Data in Sanfilippo Syndrome Type A (MPS-IIIA) Accepted for Oral Presentation at 62nd American Society of Hematology Annual Meeting

News | November 3, 2020

Orbus Therapeutics Publishes in Oncotarget Scientific Journal

Press Release | October 22, 2020

Orbus Therapeutics Expands Series A Financing to $71 Million to Support Ongoing STELLAR Phase 3 Study in Rare Brain Cancer

Press Release | October 19, 2020

Aptinyx Reports Positive, Statistically Significant, Top-line Data From Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder

Press Release | October 15, 2020

Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

Press Release | October 14, 2020

ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting

Press Release | October 9, 2020

Geeta Vemuri named Top 100 Powerful Women of 2020 by Entrepreneur

News | October 1, 2020

Skyhawk Therapeutics Named Top 11 Biotech Startup 2020 by Endpoints News

Press Release | September 17, 2020

Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

Press Release | September 10, 2020

ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01. Company Receives FDA Approval for US IND

News | August 26, 2020

Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection

News | August 17, 2020

BMS Licenses IL-12 from Dragonfly in $475 Million Upfront Deal

News | July 29, 2020

Women in Bio: Geeta Vemuri Blazes a Trail in Venture Capital

Press Release | July 27, 2020

CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy

News | July 23, 2020

Clearing the Hurdles to a Career in Venture Capital; An Interview with Geeta Vemuri

Press Release | July 16, 2020

Agent Capital Expands Management Team; Appoints Jacopo Leonardi as Partner

Press Release | July 15, 2020

Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK

Press Release | July 9, 2020

ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer

Press Release | July 9, 2020

Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collaboration

Press Release | July 8, 2020

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

News | July 6, 2020

Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases

Press Release | July 6, 2020

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

Press Release | June 26, 2020

Aptinyx to be Added to Russell 2000® Index

Press Release | June 18, 2020

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

News | June 3, 2020

Biotech Pliant Therapeutics pulls off $144M IPO to advance fibrosis pipeline

Press Release | May 28, 2020

Palvella Therapeutics Completes $45 Million Series C Financing

Press Release | May 26, 2020

Freenome Announces Initiation of the PREEMPT CRC Clinical Trial for the Early Detection and Prevention of Colorectal Cancer Using a Multiomics Blood Test

Press Release | May 19, 2020

HalioDx to Characterize the Immune Contexture of Patients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial

Press Release | May 15, 2020

New Data from Carisma Therapeutics Uncover Potential of Expedited Pathway for Immunotherapy Development Through CAR Monocytes

Press Release | May 15, 2020

Orchard Therapeutics Presents New Interim Data from OTL-203 Proof-of-concept Study for MPS-I

News | May 12, 2020

Merck doubles down on Skyhawk’s tech to drug RNA, promising $600M per autoimmune, metabolic target

News | March 31, 2020

Latest Penn biotech spinout taking on cancer raises $1.6M from investors

Press Release | March 26, 2020

First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy

News | March 23, 2020

First-of-its-kind Engineered Macrophage Cell Therapy Platform Shows Ability to Reduce Tumor Burden and Activate Anti-Tumor Immunity, Improving Overall Survival in Pre-Clinical Cancer Models

Press Release | March 23, 2020

Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis

Press Release | March 17, 2020

ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer

Press Release | March 3, 2020

Pliant Therapeutics Raises $100 Million in Series C Financing to Advance Therapies for Fibrotic Diseases

News | January 23, 2020

Business Wire Freenome Announces Encouraging Performance Data for Its Multiomics Blood Test to Detect Early-Stage Colorectal Cancer in a Prospective, Multi-Center Clinical Study

Press Release | January 8, 2020

Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)

Press Release | January 6, 2020

Carisma Therapeutics Expands Leadership Team

Press Release | December 4, 2019

ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases

Press Release | November 8, 2019

Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

Press Release | November 6, 2019

Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting

Press Release | October 28, 2019

Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting

News | October 23, 2019

Novartis bets $80M on Pliant’s preclinical NASH prospect

News | July 19, 2019

Pyxis Oncology Raises $22 Million Series A

News | July 16, 2019

Genentech inks its latest discovery deal — this time turning to RNA upstart Skyhawk

News | July 8, 2019

Fattening the bankroll, Bill Haney adds cancer R&D powerhouse Merck to Skyhawk’s roster of partners out to drug RNA

News | June 10, 2019

Aptinyx Reports Top-line Data from Phase 2 in Patients with Fibromyalgia

News | June 3, 2019

Carisma Therapeutics Names Dr. Robert Petit As Chief Scientific Officer

News | May 27, 2019

Carisma Therapeutics Featured in Nature Biotechnology’s Top Academic Spin-outs 2018

Press Release | May 14, 2019

Precision BioSciences Appoints Christopher R. Heery, M.D., as Chief Medical Officer

Press Release | May 6, 2019

Skyhawk Therapeutics Announces Agreement with Takeda for Neurodegenerative Diseases

News | April 9, 2019

Pliant Therapeutics Reports Positive Results Of Phase 1 Clinical Study

News | March 1, 2019

Genome editing company Precision proposes $100M IPO

News | January 16, 2019

Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy

Press Release | January 4, 2019

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

News | January 3, 2019

Pliant Therapeutics Initiates Phase 1 Clinical Study of PLN-74809

News | December 18, 2018

Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita

Press Release | December 18, 2018

Entrada Therapeutics Raises $59 Million Series A to Advance Intracellular Biologics Platform

Press Release | December 13, 2018

Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California

Press Release | December 6, 2018

Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space

News | November 27, 2018

Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy

News | November 20, 2018

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

News | November 5, 2018

Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering

Press Release | July 16, 2018

Pliant Therapeutics Raises $62 Million in Series B Financing

Press Release | July 16, 2018

Verge Genomics Announces $32 Million Series A

News | June 27, 2018

Carisma Nabs $53 Million Series A for Cellular Cancer Therapy

Press Release | June 26, 2018

Skyhawk Therapeutics Announces $40 Million Equity Investment Round

News | June 26, 2018

Kauffman Fellows Celebrates Its Most Diverse Group of Talented Leaders With Class 23

News | June 26, 2018

Genome Editing Startup Precision BioSciences Scores $110 Million Series B

Press Release | June 26, 2018

Precision BioSciences Raises $110M

News | June 26, 2018

Skyhawk Therapeutics Gains $100 Million Through Venture Round, Collaboration

News | June 26, 2018

CAR Macrophage Tumor Tech Created by UPenn Star Scientists Gets $53M

Press Release | June 20, 2018

Aptinyx Announces Pricing of Initial Public Offering

News | April 12, 2018

UK Gene Therapy Firm Orchard Plans Stock Offer After GSK Deal

Press Release | December 20, 2017

Orchard Therapeutics Announces $110M Series B Financing

Press Release | December 18, 2017

Aptinyx Raises $70 Million in Series B Financing